Neurocrine Biosciences | NBIX - Current Liabilities


Neurocrine Biosciences reported $874.5M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
ALKERMES USD 662.09M 62.59M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amgen USD 25.5B 547M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Exelixis USD 370.98M 34.67M Mar/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Incyte USD 1.31B 177.55M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Prothena USD 32.52M 8.33M Mar/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Repligen USD 132.66M 6.45M Jun/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Teva Pharmaceutical Industries USD 15.65B 2.11B Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026